Drug Type Monoclonal antibody |
Synonyms Anti-CemX, Anti-CEmX monoclonal antibody, FB 825 + [3] |
Target |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Food Hypersensitivity | Phase 2 | US | 30 Jan 2022 | |
Job Syndrome | Phase 2 | US | 30 Jan 2022 | |
Allergic asthma | Phase 2 | TW | 27 Jul 2021 | |
Dermatitis, Atopic | Phase 2 | TW | 06 Feb 2020 | |
Asthma | Phase 2 | TW | - | |
Rhinitis, Allergic | Phase 1 | US | - | |
Rhinitis, Allergic | Phase 1 | - | - | |
Rhinitis, Allergic | Phase 1 | - | - |
Phase 2 | - | lfqoopngby(ejxbqretvy) = ovzqeaeomx uukmnjtibl (aecjddffew ) View more | Positive | 02 May 2022 | |||
Placebo | lfqoopngby(ejxbqretvy) = nubrrkywtt uukmnjtibl (aecjddffew ) View more | ||||||
Phase 2 | 12 | zruyhxpqzz(uohfxzppmm) = ngvytybfcd qhwblhcihq (pmwiqjhhqb, smppnqyyaj - cyrrbalsqx) View more | - | 15 Mar 2021 |